2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10109A
    AS-605240 potassium 98%
    AS-605240 (potassium) is an orally active PI3Kγ inhibitor (IC50: 8 nM; Ki: 7.8 nM). AS-605240 (potassium) inhibits MCP-1- and CSF1-induced PKB phosphorylation (IC50 values are 0.181 and 0.550 µM, respectively). AS-605240 (potassium) reduces neutrophil recruitment in RANTES (CCL5)- and thioglycolate-induced peritonitis mouse models (EC50 values are 9.1 and 10 mg/kg, respectively). AS-605240 (potassium) ameliorates αCII-IA-induced arthritis in mice.
    AS-605240 potassium
  • HY-101112
    Okicenone 137018-54-3 98%
    Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation.
    Okicenone
  • HY-101132
    VB-201 630112-41-3 98%
    VB-201 is an oxidized phospholipid small molecule with anti-inflammatory activity. VB-201 inhibits CD14- and Toll-like receptor 2-dependent innate cell activation. VB-201 limits the progression of atherosclerosis and can be used to study atherosclerosis.
    VB-201
  • HY-101149
    YKL-05-093 2172616-44-1 98%
    YKL-05-093 is a salt-induced kinase (SIK) inhibitor (SIK2: Kd = 7.1 nM). YKL-05-093 reduces the phosphorylation level of HDAC4/5/CRTC2, inhibits SOST expression, and stimulates RANKL expression in vitro and in vivo. YKL-05-093 can be used in research on bone diseases.
    YKL-05-093
  • HY-101225
    8 Hydroxy PIPAT oxalate 1451210-48-2 98%
    8 Hydroxy PIPAT oxalate is a selective 5-HT1A receptor agonist that promotes the release of histamine from enteric mast cells. 8 Hydroxy PIPAT oxalate activates serotonergic signaling pathways, leading to the degranulation of mast cells in both guinea pig and human intestinal preparations. 8 Hydroxy PIPAT oxalate enhances the spontaneous release of histamine, which may contribute to the regulation of gastrointestinal functions. 8 Hydroxy PIPAT oxalate has potential implications for understanding and treating functional gastrointestinal disorders such as irritable bowel syndrome.
    8 Hydroxy PIPAT oxalate
  • HY-101234
    ICI 162846 84545-30-2 98%
    ICI 162846 is an orally active antagonist of H2 receptor. ICI 162846 inhibits acid production accompanied by an increase in the secretion of histamine in chronic duodenal ulcer (CDU) models. ICI 162846 is effective in preventing CDU.
    ICI 162846
  • HY-101235
    ICI 185282 106393-80-0 98%
    ICI 185282 is a potent, selective, orally active thromboxane A2 (TXA₂) receptor antagonist. ICI 185282 causes dose-dependent inhibition of U-46619 (HY-108566)-induced platelet aggregation ex-vivo in guinea-pig. ICI 185,282 inhibits bronchospasm induced by U-46619, PGD2 (HY-101988), PGF2α (HY-12956), arachidonic acid (HY-109590), LTD4 and PAF (HY-108635) in vivo. ICI 185282 can be used for bronchial asthma research.
    ICI 185282
  • HY-101337
    Imiloxan 81167-16-0 98%
    Imiloxan (RS 21361) is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan produces a dose-related reversal of Guanoxabenz (HY-U00123)-induced maximal mydriasis in male rats. Imiloxan has the potential for acute kidney injury research.
    Imiloxan
  • HY-101579
    LY 178002 107889-32-7 99.60%
    LY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
    LY 178002
  • HY-101654
    Rocepafant 132579-32-9 98%
    Rocepafant (BN 50730) is a specific platelet activating factor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research.
    Rocepafant
  • HY-101670
    MTPPA 70991-61-6 99.82%
    MTPPA ((Rac)-M-5011) is an orally active anti-inflammatory, analgesic and anti-rheumatic compound. MTPPA mediates the inhibition of prostaglandin biosynthesis. MTPPA acts as a four-point tetrahedral organophosphonate bridging ligand. MTPPA can be used in research related to inflammation, pain and adjuvant arthritis.
    MTPPA
  • HY-101678
    Alinastine 154541-72-7 98%
    Alinastine is a new antihistamine agent.
    Alinastine
  • HY-101689
    Benzpiperylone 53-89-4 98%
    Benzpiperylone (KB 95) is a synthetic drug with potent anti-inflammatory properties.
    Benzpiperylone
  • HY-101822
    Naminterol 93047-40-6 98%
    Naminterol is a phenethanolamine derivative, is a β2 adrenoceptor agonist with bronchodilatory properties. Naminterol is used for treatment of asthma.
    Naminterol
  • HY-101828
    Guaiapate 852-42-6 98%
    Guaiapate is an antitussive agent.
    Guaiapate
  • HY-101871
    Trehalose 6-behenate 66755-19-9 98%
    Trehalose 6-behenate is a Th1/Th17 skewing vaccine adjuvant.
    Trehalose 6-behenate
  • HY-101945
    A-69412 123606-23-5 98%
    A-69412 is a reversible, specific inhibitor of the 5-lipoxygenase (5-LO). A-69412 has the potential to treat asthma and ulcerative colitis, and possibly other inflammatory and allergic conditions.
    A-69412
  • HY-10252A
    cis-NVP-ADW742 475489-15-7 98%
    cis-NVP-ADW742 (cis-ADW742) is a cis isomer of NVP-ADW742 (HY-10252). NVP-ADW742 is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells.
    cis-NVP-ADW742
  • HY-10291R
    Tarenflurbil (Standard) 51543-40-9 98%
    Tarenflurbil (Standard) is the analytical standard of Tarenflurbil. This product is intended for research and analytical applications. Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [3H]9-cis-RA to RXRα LBD with IC50 of 75 μM. Tarenflurbil can be used for Alzheimer's disease research.
    Tarenflurbil (Standard)
  • HY-103055
    PPTN mesylate 1160271-31-7 98%
    PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.
    PPTN mesylate
Cat. No. Product Name / Synonyms Application Reactivity